Invion Stock

Invion SGA/Revenue

SGA to Revenue Ratio of Invion (IVX.AX) as of Aug 23, 2026.

SGA/Revenue

0.00

Last updated:

SGA to Revenue Ratio of Invion is 2026 0.00 . SGA to Revenue Ratio of Invion was 2025 152.25 % . It decreases by % lower compared to the previous year.

The Invion SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2016
2,491.84 AUD
Jan 1, 2018
153.91 AUD
Jan 1, 2019
92.47 AUD
Jan 1, 2020
75.74 AUD
Jan 1, 2021
89.94 AUD
Jan 1, 2022
87.13 AUD
Jan 1, 2023
52.91 AUD
Jan 1, 2024
152.25 AUD
The Invion SGA/Revenue history
YEARSGA/RevenueYoY
152.25 %+187.73%
52.91 %-39.27%
87.13 %-3.13%
89.94 %+18.76%
75.74 %-18.10%
92.47 %-39.92%
153.91 %-93.82%
2,491.84 %+10.93%
2,246.38 %+54.92%
1,450.00 %
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Invion since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

Margins — Invion

All Key Metrics — Invion